The VanEck Healthcare TrueSector ETF seeks long-term capital growth by investing in healthcare-related companies and in instruments that provide exposure to the industry. It selects companies within the sector through active management, and its design aims to cover a broad range of market capitalizations.

It may suit investors who want to adjust their healthcare allocation separately and who can accept the changes in holdings and the volatility that come with active management.

This is an actively managed ETF run by VanEck.

The fund builds its portfolio using equity securities of healthcare-related companies and instruments that provide exposure to the industry. Unlike a simple index-replication approach, it reflects the manager's judgment, so performance may diverge from a comparison index depending on the sector environment and company-specific characteristics.

• A structure that aims for broad market-cap exposure within the healthcare sector
• A management approach intended to ease the persistent underweighting of large constituents

Assets under management (AUM) stand at $0.6M, and the total expense ratio is 0.10% per year.

Because the fund is actively managed, its actual holdings and performance may vary with the manager's decisions. When comparing it with index-tracking healthcare ETFs, it is better to look not only at fees but also at how holdings are selected, trading conditions and the consistency of sector exposure.

Returns in the healthcare sector can be affected by drug development news, demand for medical services, regulatory decisions, the cost environment and corporate earnings. Because TRUH is actively managed, performance differences may arise not only from the overall direction of the market but also from the results of individual stock selection.

Healthcare includes areas where demand can hold up regardless of the economic cycle, but fund flows can shift depending on growth expectations within the industry and regulatory variables. Demand to adjust sector allocations and trading conditions can affect the effective cost of buying and selling.

The active approach to the healthcare sector is a strength, but sector concentration, performance gaps resulting from management decisions and the absence of a distribution history are factors to keep in mind.

In the comparison table, XLV is a product that investors seeking broad access to the healthcare sector can compare. With VHT, you can look at the fee burden and the difference in fund manager, and with XBI, the more sensitive exposure to the biotech industry. Because IYH and FHLC may each differ in their benchmark and trading conditions, they should be compared alongside the active management structure and the absence of a distribution history for TRUH.

When looking at TRUH, first confirm whether the goal of increasing your healthcare weighting fits your existing asset mix. Active management can produce a performance path that differs from index-tracking products, so you need to review fees, trading conditions and distribution history together.

Healthcare-related companies can be affected by regulatory decisions, R&D results, the patent environment, cost burdens and changes in the competitive landscape. Because the manager's judgment weighs heavily on the performance of actively managed products, it is worth understanding in advance how they differ from index-tracking products and what their trading conditions are.

TRUH may be a candidate for investors who want to actively add healthcare sector exposure. However, the absence of a distribution history and the risk of sector concentration must be taken into account, and when comparing it with index-tracking products, it is appropriate to review fees, management style, the likelihood of changes in holdings and actual trading conditions together.